GSK homepage Annual Report
Annual review Downloads


 
The Operating and financial review and prospects discusses the operating and financial performance of the Group, the financial outlook and the financial resources of the Group, under the following headings:

The results for each year are compared primarily with the results for the preceding year. Reference is made also to quarterly and half-yearly trends within the results.

Exchange
The Group, as a multinational business, operates in many countries and earns revenues and incurs costs in many currencies. The results of the Group, as reported in sterling, are therefore affected by movements in exchange rates between sterling and overseas currencies.

The company uses the average exchange rates prevailing during the period to translate the results and cash flows of overseas Group subsidiary, joint venture and associated undertakings into sterling and period end rates to translate the net assets of those undertakings. The currencies which most influence these translations are the US dollar, the euro and the Japanese yen.

In order to illustrate underlying business performance, excluding the effect of exchange rate movements on translation, it is the Group’s practice to discuss its results in terms of constant exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to translate the results of overseas companies into sterling had remained unchanged from those used in the previous period. The discussion in this review is therefore in terms of CER unless otherwise stated.

 

   
  Back to top
  Updated March 22, 2001 - © 2001 GlaxoSmithKline - All Rights Reserved
Legal Notices - Privacy Statement